{"id":12,"date":"2020-12-14T14:51:26","date_gmt":"2020-12-14T12:51:26","guid":{"rendered":"https:\/\/www.oramanetwork.gr\/en\/?page_id=12"},"modified":"2022-11-14T20:48:37","modified_gmt":"2022-11-14T18:48:37","slug":"objectives","status":"publish","type":"page","link":"https:\/\/www.oramanetwork.gr\/en\/?page_id=12","title":{"rendered":"Objectives"},"content":{"rendered":"<hr \/>\n<blockquote><p><span style=\"color: #b20101;\">The objective of the project is the development of an innovative anti-cancer product (cytostatic-antineoplastic) with targeted action on cancer cells that carry the gonadotropin releasing hormone receptors GnRH (Gonadotropin Releasing Hormone or LHRH: Luteinizing Hormone-Releasing Hormone).<\/span><\/p><\/blockquote>\n<p>GnRH is a decapeptide, which is produced in the hypothalamus and released by impulses, that controls the release of the gonadotropin hormones LH (Luteinizing Hormone) and FSH (Follicle Stimulating Hormone).<\/p>\n<p>GnRH receptors are considered targets for the treatment of hormone-dependent cancers as they are highly expressed in different types of cancer cells.<\/p>\n<p>They are expressed in 80 % and 86 % of ovarian and endometrial cancers and 50 % in prostate and breast cancers. Targeted cancer treatment is a challenge, not only for the scientific community, but also for the pharmaceutical industry.<\/p>\n<p>The goal is to reduce the side effects of chemotherapy with better efficacy. The use of a GnRH peptide analogues linked to cytostatic \/ cytotoxic agents may be a successful approach to the development of targeted therapy by reducing the serious side effects of cytotoxic drugs.<\/p>\n<p>The development of the proposed improved and targeted cancer treatment includes the following actions:<\/p>\n<ul>\n<li><span style=\"color: #b20101;\"><strong>(i)<\/strong><\/span> rational design and synthesis of product;<\/li>\n<li><span style=\"color: #b20101;\"><strong>(ii)<\/strong><\/span> <em>in vitro<\/em> evaluation and pharmacological studies (binding, endocytosis and signaling studies) using different types of cancer cells that express GnRH receptor;<\/li>\n<li><span style=\"color: #b20101;\"><strong>(iii)<\/strong><\/span> stability studies and<\/li>\n<li><span style=\"color: #b20101;\"><strong>(iv)<\/strong><\/span> <em>in vivo<\/em> evaluation of synthesised product in experimental hormone-dependent cancer animal model.<\/li>\n<\/ul>\n<p>The company <strong>Excelya (formerly ZeinCRO)<\/strong> as well as the collaborating research teams <strong>Department of Chemistry, University of Patras<\/strong> (Body 2) and <strong>Medical School, University of Crete<\/strong> (Body 3)] have the reliability, experience, know-how, appropriate equipment and scientific competence to achieve the goal of the project, the development of a targeted treatment for hormone-dependent cancer.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The objective of the project is the development of an innovative anti-cancer product (cytostatic-antineoplastic) with targeted action on cancer cells that carry the gonadotropin releasing hormone receptors GnRH (Gonadotropin Releasing Hormone or LHRH: Luteinizing Hormone-Releasing Hormone). GnRH is a decapeptide, which is produced in the hypothalamus and released by impulses, that controls the release of &#8230; <a title=\"Objectives\" class=\"read-more\" href=\"https:\/\/www.oramanetwork.gr\/en\/?page_id=12\" aria-label=\"Read more about Objectives\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-12","page","type-page","status-publish"],"_links":{"self":[{"href":"https:\/\/www.oramanetwork.gr\/en\/index.php?rest_route=\/wp\/v2\/pages\/12","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.oramanetwork.gr\/en\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.oramanetwork.gr\/en\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.oramanetwork.gr\/en\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.oramanetwork.gr\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12"}],"version-history":[{"count":12,"href":"https:\/\/www.oramanetwork.gr\/en\/index.php?rest_route=\/wp\/v2\/pages\/12\/revisions"}],"predecessor-version":[{"id":276,"href":"https:\/\/www.oramanetwork.gr\/en\/index.php?rest_route=\/wp\/v2\/pages\/12\/revisions\/276"}],"wp:attachment":[{"href":"https:\/\/www.oramanetwork.gr\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}